Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.
This drug was developed by Regeneron Pharmaceuticals, Inc.[2] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.